⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18726539 | 0.79 | — | — | |
| SCHEMBL14616062 | 0.69 | — | — | |
| SCHEMBL19413514 | 0.67 | — | — | |
| SCHEMBL18674866 | 0.65 | — | — | |
| SCHEMBL1533841 | 0.65 | PPARA (0.32) | — | |
| SCHEMBL28448217 | 0.65 | — | — | |
| SCHEMBL31119911 | 0.62 | — | — | |
| SCHEMBL12424775 | 0.61 | — | — | |
| SCHEMBL2135440 | 0.61 | — | — | |
| SCHEMBL7178107 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658652-A2 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4626432-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MRTX0902 | Mirati Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4511372-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025024449-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MRTX1133 | Mirati Therapeutics, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025024447-A2 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MRTX1133 | Mirati Therapeutics, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240400558-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | MIRATI THERAPEUTICS, INC | 2024-12-05 | — | — | US | disclosed |
| WO-2024163626-A2 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4398897-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228705-A1 | RESIN COMPOSITION | NAN YA PLASTICS CORPORATION (TW) | 2024-07-11 | — | — | US | disclosed |
| WO-2024118348-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MRTX0902 | Mirati Therapeutics, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| WO-2008021944-A2 | POTENTIATION OF ANTIFUNGAL COMPOUNDS | METHYLGENE INC. (CA) | 2008-02-21 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007107005-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE, INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| US-20070197550-A1 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | 92229129 QUEBEC INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2007072179-A2 | HISTONE DEACETYLASE INHIBITORS FOR ENHANCING ACTIVITY OF ANTIFUNGAL AGENTS | METHYLGENE, INC. (CA) | 2007-06-28 | — | — | WO | disclosed |